| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3904656 | Urology | 2008 | 5 Pages |
Abstract
The results of this study demonstrated that PAP is a stronger predictor of CSS than PSA or Gleason score in men with higher risk prostate cancer treated with 103Pd brachytherapy and EBRT. Given the findings of this analysis, the use of PAP should be reconsidered in these patients.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
L. Christine Fang, Michael Dattoli, Al Taira, Lawrence True, Richard Sorace, Kent Wallner,